Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. His presentation is scheduled for September 14 at 11:00 a.m. Eastern Time. A live webcast will be accessible through the company's website, with a replay available post-conference. Revolution Medicines focuses on precision oncology, developing targeted therapies for RAS-addicted cancers, including RMC-4630 and RMC-5552, aimed at inhibiting critical cancer signaling pathways.
Revolution Medicines (Nasdaq: RVMD) will participate in the 2nd Annual RAS-Targeted Drug Development Conference from September 14-16, 2020. Key presentations include:
- Title: Approaches to Inhibiting RAS Driven Tumors Beyond KRAS G12C
Presenter: Steve Kelsey, M.D.
Date: September 16, 2020, 9:00 a.m. Eastern - Title: Empowering Combination Strategies to Target RAS Mutant Cancers
Participant: Jan Smith, Ph.D.
Date: September 16, 2020, 4:30 p.m. Eastern - Workshop: Navigating the Future Potential of Combination Strategies
Co-Leader: Jan Smith, Ph.D.
Date: September 14, 2020, 11:30 a.m. Eastern
Revolution Medicines (Nasdaq: RVMD) announced the closing of a public offering of 6,900,000 shares at $26.00 each, generating gross proceeds of $179.4 million before deductions. The offering included 900,000 additional shares purchased by underwriters. The funds are expected to support the company’s focus on developing targeted cancer therapies, specifically those targeting RAS and mTOR pathways. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities managed the offering.
Revolution Medicines has announced a public offering of 6,000,000 shares of common stock at a price of $26.00 per share, aiming to raise approximately $156 million before expenses. The offering includes an option for underwriters to purchase up to 900,000 additional shares. The offering is set to close on July 13, 2020, subject to standard closing conditions. Notable financial institutions involved include J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities.
Revolution Medicines, Inc. (Nasdaq: RVMD) has launched an underwritten public offering of 5,500,000 shares of common stock. The company plans to grant underwriters a 30-day option to purchase an additional 825,000 shares. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities are serving as joint book-running managers for the offering. A registration statement has been filed with the SEC, but it is not yet effective. This press release does not constitute an offer to sell or a solicitation to buy securities.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the publication of research in the Proceedings of the National Academy of Sciences detailing a compound, WDB002, that inhibits the CEP250 protein, which may also target SARS-CoV-2. This discovery could lead to new antiviral candidates. The company has licensed the intellectual property to Ginkgo Bioworks for further development against infectious diseases. Revolution Medicines remains focused on oncology therapies while exploring the antiviral potential of WDB002, collaborating with Ginkgo to expedite research efforts in the face of COVID-19.
Revolution Medicines (Nasdaq: RVMD) provided a comprehensive R&D update on June 22, 2020, focusing on advancements in their RMC-4630 clinical program aimed at treating RAS cancers. Key highlights include improved pharmacokinetics and tolerability from intermittent dosing, anti-tumor activity data in non-small cell lung cancer patients with KRAS mutations, and promising results from novel dual-target therapies in preclinical models. The company continues to expand its innovative pipeline, emphasizing targeted therapies within the RAS and mTOR pathways.
Revolution Medicines (Nasdaq: RVMD) announced the dosing of the first patient in a multicenter Phase 1 clinical trial for RMC-4630 (SAR442720), a SHP2 inhibitor, in combination with pembrolizumab (Keytruda). This trial targets patients with advanced malignancies like non-small cell lung cancer and colorectal cancer. The study aims to evaluate safety and preliminary efficacy. Previous research suggests that RMC-4630 may enhance anti-tumor effects when used with immune checkpoint inhibitors. The company aims to explore broader applications of RMC-4630 in RAS-dependent tumors.
Revolution Medicines, Inc. (Nasdaq: RVMD) has appointed Eric T. Schmidt, Ph.D., and Peter Svennilson to its board of directors. Schmidt, previously CFO at Allogene Therapeutics, brings extensive biotechnology experience from Wall Street, while Svennilson has over 35 years in venture capital and finance. Their appointments aim to enhance the company's financial expertise as it matures. This follows the resignation of Larry Lasky, Ph.D., who will remain a scientific advisor. Revolution Medicines focuses on targeted therapies for cancer, with a robust pipeline including RMC-4630 and other key oncology targets.
Revolution Medicines (Nasdaq: RVMD) has initiated dosing in a Phase 1b clinical trial for its investigational SHP2 inhibitor, RMC-4630, combined with Amgen's KRASG12C inhibitor, AMG 510. The trial targets advanced solid tumors with the KRASG12C mutation, focusing on safety, tolerability, and efficacy. RMC-4630 aims to overcome resistance in RAS-dependent tumors and is part of a broader therapeutic strategy involving multiple combination treatments. This trial marks a significant step in Revolution Medicines' efforts to advance cancer therapies targeting the RAS pathway.